Immune Modulation by Exosomes in COVID-19
Recruiting
Observational Study
COVID-19
Critical Illness
Hypercytokinemia
Lung Fibrosis
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- University of Ulm · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Critically ill COVID-19 patients with lung dysfunction
* COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020)
* Body weight \> 50 kg
* Informed consent
Exclusion Criteria:
* Pregnant or breast feeding women
Contacts